Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis
Abstract
1. Introduction
2. Materials and Methods
2.1. Human Tissue Samples
2.2. Immunofluorescence for Skin Tissue
2.3. AD Patient Recruitment and Blood Samples
2.4. Isolation of PBMCs from whole blood
2.5. Fluorescence-Activated Cell Sorting
2.6. Immunofluorescence for PBMC
2.7. Enzyme-Linked Immunosorbent Assay for IL-31
2.8. Statistical Analysis
3. Results
3.1. Co-Localization of H4R and IL-31 in Lesional AD Skin
3.2. Characteristics of AD Patients
3.3. Comparison of CD45RO+CLA+H4R+ T Cells in Patients with AD and Healthy Controls
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
4MH | 4-methylhistamine dihydrochloride |
AD | atopic dermatitis |
BSA | bovine serum albumin |
CLA | cutaneous lymphocyte-associated antigen |
FACS | fluorescence-activated cell sorting |
H1R | histamine-1-receptor |
H4R | histamine-4-receptor |
IF | immunofluorescence |
IL | interleukin |
JAK | Janus kinase |
PBMC | peripheral blood mononuclear cell |
SEB | staphylococcal enterotoxin B |
TSLP | thymic stromal lymphopoietin |
References
- Dillon, S.R.; Sprecher, C.; Hammond, A.; Bilsborough, J.; Rosenfeld-Franklin, M.; Presnell, S.R.; Haugen, H.S.; Maurer, M.; Harder, B.; Johnston, J.; et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004, 5, 752–760. [Google Scholar] [CrossRef] [PubMed]
- Bagci, I.S.; Ruzicka, T. IL-31: A new key player in dermatology and beyond. J. Allergy Clin. Immunol. 2018, 141, 858–866. [Google Scholar] [CrossRef] [PubMed]
- Ezzat, M.H.; Hasan, Z.E.; Shaheen, K.Y. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: Elevated levels correlate with severity scoring. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 334–339. [Google Scholar] [CrossRef] [PubMed]
- Ruzicka, T.; Hanifin, J.M.; Furue, M.; Pulka, G.; Mlynarczyk, I.; Wollenberg, A.; Galus, R.; Etoh, T.; Mihara, R.; Yoshida, H.; et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N. Engl. J. Med. 2017, 376, 826–835. [Google Scholar] [CrossRef] [PubMed]
- Bilsborough, J.; Leung, D.Y.; Maurer, M.; Howell, M.; Boguniewicz, M.; Yao, L.; Storey, H.; LeCiel, C.; Harder, B.; Gross, J.A. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2006, 117, 418–425. [Google Scholar] [CrossRef]
- Stott, B.; Lavender, P.; Lehmann, S.; Pennino, D.; Durham, S.; Schmidt-Weber, C.B. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J. Allergy Clin. Immunol. 2013, 132, 446–454 e445. [Google Scholar] [CrossRef] [PubMed]
- Cevikbas, F.; Wang, X.; Akiyama, T.; Kempkes, C.; Savinko, T.; Antal, A.; Kukova, G.; Buhl, T.; Ikoma, A.; Buddenkotte, J.; et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J. Allergy Clin. Immunol. 2014, 133, 448–460. [Google Scholar] [CrossRef] [PubMed]
- Maier, E.; Werner, D.; Duschl, A.; Bohle, B.; Horejs-Hoeck, J. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-kappaB-dependent way. J. Immunol. 2014, 193, 645–654. [Google Scholar] [CrossRef] [PubMed]
- Cornelissen, C.; Brans, R.; Czaja, K.; Skazik, C.; Marquardt, Y.; Zwadlo-Klarwasser, G.; Kim, A.; Bickers, D.R.; Luscher-Firzlaff, J.; Luscher, B.; et al. Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells. Br. J. Dermatol. 2011, 165, 966–975. [Google Scholar] [CrossRef]
- Thurmond, R.L.; Gelfand, E.W.; Dunford, P.J. The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. Nat. Rev. Drug. Discov. 2008, 7, 41–53. [Google Scholar] [CrossRef]
- Gutzmer, R.; Mommert, S.; Gschwandtner, M.; Zwingmann, K.; Stark, H.; Werfel, T. The histamine H4 receptor is functionally expressed on T(H)2 cells. J. Allergy Clin. Immunol. 2009, 123, 619–625. [Google Scholar] [CrossRef]
- Ohsawa, Y.; Hirasawa, N. The role of histamine H1 and H4 receptors in AD. Allergol. Int. 2014, 63, 10. [Google Scholar] [CrossRef]
- Raap, U.; Gehring, M.; Kleiner, S.; Rudrich, U.; Eiz-Vesper, B.; Haas, H.; Kapp, A.; Gibbs, B.F. Human basophils are a source of—and are differentially activated by—IL-31. Clin. Exp. Allergy 2017, 47, 499–508. [Google Scholar] [CrossRef]
- Feld, M.; Garcia, R.; Buddenkotte, J.; Katayama, S.; Lewis, K.; Muirhead, G.; Hevezi, P.; Plesser, K.; Schrumpf, H.; Krjutskov, K.; et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J. Allergy Clin. Immunol. 2016, 138, 500–508 e524. [Google Scholar] [CrossRef]
- Park, K.; Park, J.H.; Yang, W.J.; Lee, J.J.; Song, M.J.; Kim, H.P. Transcriptional activation of the IL31 gene by NFAT and STAT6. J. Leukoc. Biol. 2012, 91, 245–257. [Google Scholar] [CrossRef]
- Jutel, M.; Watanabe, T.; Akdis, M.; Blaser, K.; Akdis, C.A. Immune regulation by histamine. Curr. Opin. Immunol. 2002, 14, 6. [Google Scholar] [CrossRef]
- Werfel, T.; Layton, G.; Yeadon, M.; Whitlock, L.; Osterloh, I.; Jimenez, P.; Liu, W.; Lynch, V.; Asher, A.; Tsianakas, A.; et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2019, 143, 1830–1837e1834. [Google Scholar] [CrossRef]
- Rossbach, K.; Wendorff, S.; Sander, K.; Stark, H.; Gutzmer, R.; Werfel, T.; Kietzmann, M.; Baumer, W. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp. Dermatol. 2009, 18, 57–63. [Google Scholar] [CrossRef]
- Seike, M.; Furuya, K.; Omura, M.; Hamada-Watanabe, K.; Matsushita, A.; Ohtsu, H. Histamine H(4) receptor antagonist ameliorates chronic allergic contact dermatitis induced by repeated challenge. Allergy 2010, 65, 319–326. [Google Scholar] [CrossRef]
- Dunford, P.J.; Williams, K.N.; Desai, P.J.; Karlsson, L.; McQueen, D.; Thurmond, R.L. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 2007, 119, 176–183. [Google Scholar] [CrossRef]
- Murata, Y.; Song, M.; Kikuchi, H.; Hisamichi, K.; Xu, X.L.; Greenspan, A.; Kato, M.; Chiou, C.F.; Kato, T.; Guzzo, C.; et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J. Dermatol. 2015, 42, 129–139. [Google Scholar] [CrossRef] [PubMed]
- Kollmeier, A.; Francke, K.; Chen, B.; Dunford, P.J.; Greenspan, A.J.; Xia, Y.; Xu, X.L.; Zhou, B.; Thurmond, R.L. The histamine H(4) receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J. Pharmacol. Exp. Ther. 2014, 350, 181–187. [Google Scholar] [CrossRef] [PubMed]
- Dijkstra, D.; Stark, H.; Chazot, P.L.; Shenton, F.C.; Leurs, R.; Werfel, T.; Gutzmer, R. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J. Investig. Dermatol. 2008, 128, 1696–1703. [Google Scholar] [CrossRef] [PubMed]
- Gutzmer, R.; Diestel, C.; Mommert, S.; Kother, B.; Stark, H.; Wittmann, M.; Werfel, T. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J. Immunol. 2005, 174, 5224–5232. [Google Scholar] [CrossRef]
- Glatzer, F.; Gschwandtner, M.; Ehling, S.; Rossbach, K.; Janik, K.; Klos, A.; Baumer, W.; Kietzmann, M.; Werfel, T.; Gutzmer, R. Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor. J. Allergy Clin. Immunol. 2013, 132, 1358–1367. [Google Scholar] [CrossRef]
- Schaper, K.; Rossbach, K.; Kother, B.; Stark, H.; Kietzmann, M.; Werfel, T.; Gutzmer, R. Stimulation of the histamine 4 receptor upregulates thymic stromal lymphopoietin (TSLP) in human and murine keratinocytes. Pharmacol. Res. 2016, 113, 209–215. [Google Scholar] [CrossRef]
- Renert-Yuval, Y.; Guttman-Yassky, E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann. Allergy Asthma. Immunol. 2020, 124, 28–35. [Google Scholar] [CrossRef]
- Thaçi, D.; Simpson, E.L.; Beck, L.A.; Bieber, T.; Blauvelt, A.; Papp, K.; Soong, W.; Worm, M.; Szepietowski, J.C.; Sofen, H.; et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016, 387, 40–52. [Google Scholar] [CrossRef]
- Simpson, E.L.; Bieber, T.; Guttman-Yassky, E.; Beck, L.A.; Blauvelt, A.; Cork, M.J.; Silverberg, J.I.; Deleuran, M.; Kataoka, Y.; Lacour, J.P.; et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N. Engl. J. Med. 2016, 375, 2335–2348. [Google Scholar] [CrossRef]
- Blauvelt, A.; de Bruin-Weller, M.; Gooderham, M.; Cather, J.C.; Weisman, J.; Pariser, D.; Simpson, E.L.; Papp, K.A.; Hong, H.C.-H.; Rubel, D.; et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017, 389, 2287–2303. [Google Scholar] [CrossRef]
- Guttman-Yassky, E.; Silverberg, J.I.; Nemoto, O.; Forman, S.B.; Wilke, A.; Prescilla, R.; de la Pena, A.; Nunes, F.P.; Janes, J.; Gamalo, M.; et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J. Am. Acad. Dermatol. 2019, 80, 913–921 e919. [Google Scholar] [CrossRef]
- Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: Results from a randomized double-blind placebo-controlled study. Br. J. Dermatol. 2019, 181, 733–742. [Google Scholar] [CrossRef]
- Guttman-Yassky, E.; Pavel, A.B.; Zhou, L.; Estrada, Y.D.; Zhang, N.; Xu, H.; Peng, X.; Wen, H.C.; Govas, P.; Gudi, G.; et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2019, 144, 482–493e487. [Google Scholar] [CrossRef]
- Guttman-Yassky, E.; Brunner, P.M.; Neumann, A.U.; Khattri, S.; Pavel, A.B.; Malik, K.; Singer, G.K.; Baum, D.; Gilleaudeau, P.; Sullivan-Whalen, M.; et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J. Am. Acad. Dermatol. 2018, 78, 872–881 e876. [Google Scholar] [CrossRef]
- Czarnowicki, T.; He, H.; Krueger, J.G.; Guttman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. J. Allergy Clin. Immunol. 2019, 143, 1–11. [Google Scholar] [CrossRef]
Target | Primary Antibody | Secondary Antibody | |||
---|---|---|---|---|---|
Clonality | Host | Fluorophore | Reactivity | Host | |
CD3 | Monoclonal | Human | Alexa fluor® 405 | Conjugated | |
CD45RO | Monoclonal | Mouse | Alexa fluor® 488 | Mouse | Goat |
CLA | Monoclonal | Rat | Allophycocyanin | Rat | Goat |
H4R | Polyclonal | Rabbit | PE-cyanine 5.5 | Rabbit | Goat |
Case ID | Age | Sex | IgE (IU/mL) | Biopsy Site |
---|---|---|---|---|
1 | 5 | M | NA | Back |
2 | 23 | F | NA | Back |
3 | 24 | F | 2280 | Thigh |
4 | 37 | F | 2153 | Lowe leg |
5 | 62 | M | 3412 | Face |
Total | 30.2 ± 21.1 | 2615 ± 693 |
Case ID | Age | Sex | Eosinophils (%) | IgE (IU/mL) | ECP (ng/mL) | SCORAD |
---|---|---|---|---|---|---|
AD1 | 20 | M | 8.2 | NA | NA | 54.6 |
AD2 | 19 | M | 2.2 | 1284 | 26.7 | 39.5 |
AD3 | 36 | F | 10.1 | 2346 | 46.5 | 35.0 |
AD4 | 20 | M | 7.5 | 5369 | 114 | 49.1 |
AD5 | 35 | F | 6.9 | 1968 | 122 | 35.9 |
AD6 | 26 | M | 10.9 | 13,600 | NA | 56.5 |
AD7 | 24 | F | 7.0 | 3349 | 114 | 51.5 |
AD8 | 25 | M | 13.0 | 5991 | NA | 77.6 |
Total | 25.6 ± 6.6 | 8.2 ± 3.2 | 4843.9 ± 4236.3 | 84.6 ± 44.5 | 50.0 ± 14.0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bang, C.H.; Song, J.Y.; Song, Y.M.; Lee, J.H.; Park, Y.M.; Lee, J.Y. Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis. J. Clin. Med. 2021, 10, 1976. https://doi.org/10.3390/jcm10091976
Bang CH, Song JY, Song YM, Lee JH, Park YM, Lee JY. Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis. Journal of Clinical Medicine. 2021; 10(9):1976. https://doi.org/10.3390/jcm10091976
Chicago/Turabian StyleBang, Chul Hwan, Ji Young Song, Yu Mee Song, Ji Hyun Lee, Young Min Park, and Jun Young Lee. 2021. "Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis" Journal of Clinical Medicine 10, no. 9: 1976. https://doi.org/10.3390/jcm10091976
APA StyleBang, C. H., Song, J. Y., Song, Y. M., Lee, J. H., Park, Y. M., & Lee, J. Y. (2021). Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis. Journal of Clinical Medicine, 10(9), 1976. https://doi.org/10.3390/jcm10091976